ACT-GLOBAL Adaptive Platform Trial for Stroke

ConditionStroke
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe George Institute

About this trial

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Eligibility criteria

Qualifiers

Age ≥18 years

Clinical diagnosis of stroke

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Standard-dose intravenous tenecteplase
  • Low-dose intravenous tenecteplase
  • No intravenous tenecteplase
  • Conservative Blood Pressure Control
  • Moderate Blood Pressure Control
  • Intensive Blood Pressure Control
  • Placebo
  • NoNO-42
  • No deferoxamine mesylate and no colchicine
  • Deferoxamine mesylate only
  • Colchicine only
  • Both deferoxamine mesylate and colchicine

Treatment groups

20,000 Participants
are divided into 4 treatment groups

Sponsors and collaborators

The George Institute

Lead sponsor

University of Calgary

Collaborator

Berry Consultants

Collaborator